Trial Profile

An open label, 52 week clinical trial of glatiramer acetate in patients with relapsing-remitting multiple sclerosis in Japan

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 02 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Glatiramer acetate (Primary)
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Sponsors Teva Pharmaceutical Industries

Most Recent Events

28 Sep 2015 According to a Takeda media release, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application for Glatiramer acetate (Copaxone) subcutaneous injection 20 mg syringe for the treatment of multiple sclerosis. The approval is based on the results of this and three other overseas clinical trials conducted by Teva in patients with relapsing- remitting multiple sclerosis.
30 Jul 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com